

## CHARITÉ TO BECOME 2ND SITE FOR VISABL-VT

**19 December 2025** – Melbourne, Australia (**18 December 2025** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (Company or **Imricor**) (ASX: **IMR**) is excited to announce that the Charité University Hospital, in Berlin, Germany (**Charité**), will be the second site, worldwide, to join the VISABL-VT clinical trial.

The Principal Investigator (**PI**) for VISABL-VT at Charité will be Professor Dr Felix Hohendanner, Senior Electrophysiologist and Head of Charité's Cardiac Catheterization Laboratories.

Professor Dr Gerhard Hindricks, Head of Electrophysiology and Director of Cardiology at Charité, will oversee the entire project. Professor Hindricks is a worldwide thought leader in the field of electrophysiology and a past president of the European Heart Rhythm Association.

Charité is consistently ranked in the top 10 hospitals worldwide, by Newsweek and U.S. News & World Report, and it houses more than half of the German Nobel Prize winners in medicine and physiology.

**Imricor's Chair and CEO, Steve Wedan, commented:** “We are absolutely thrilled to have Germany's most prestigious hospital join our VISABL-VT trial, a trial we expect to change the world of electrophysiology forever. Our earliest clinical work started at the Leipzig Heart Center, under the direction of Professor Hindricks, and now he is able to rejoin us once again at Charité to help lead the world with real-time MRI-guided ablations.

“Today's huge step forward is made possible by the teams at Imricor and Philips, who collaborated over the past several years to deliver our most recent and advanced tools, such as NorthStar and our second-generation Vision-MR ablation catheter on the Philips MRI platform. Many thanks to all involved.”

### Next Steps

Upon upgrading the software of their Philips MRI scanner, it is possible to connect Imricor's NorthStar to the Philips MRI system, which allows complex ablation procedures such ventricular tachycardia (VT) ablations to be performed in a Philips-based iCMR lab. Submission to Ethics Committee and the German Competent Authority (**BfArM**) were made to enable Charité to join the VISABL-VT trial. BfArM previously approved VISABL-VT, but new updates to the previously-approved study have since been made. New updates include the combination of Phillips MRI systems with NorthStar, as well as moving Imricor's now-commercial CE marked devices out of the study, since they are no longer investigational devices and can instead be used under their CE mark approvals. This drastically simplifies the study.

The electrophysiology team at Charité will also perform commercial atrial flutter ablations in the MRI lab as a part of their routine clinical work prior to, and concurrently with, the VISABL-VT trial. Atrial flutter ablations are expected to commence in Q1 2026.

### ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO



## Media and Investor Relations Contacts:

Simon Hinsley  
Executive Director, NWR  
[simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)  
+61 401 909 653

Nick Corkill  
VP Corporate Strategy, Imricor  
[nick.corkill@imricor.com](mailto:nick.corkill@imricor.com)  
+61 450 475 633

### About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

### Imricor's Products

Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. US FDA approval is in process, and further approvals in other geographies such as Australia are being planned.

### Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.